LifeMD (LFMD) Stock Forecast & Price Target

Compare

621 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LFMD Analyst Ratings

Strong Buy

4 Buy

1 Hold

0 Sell

Based on 5 analysts giving stock ratings to

LifeMD

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LFMD Stock 12 Month Forecast

Average Price Target

$14.60

▲(44.70%Upside)

Based on 5 Wall Street analysts offering 12 month price targets for LifeMD in the last 3 months. The average price target is $14.60 with a high forecast of $18.00 and a low forecast of $8.00. The average price target represents a 44.70% change from the last price of $10.09.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","7":"$7","11":"$11","15":"$15","19":"$19"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,7,11,15,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.13,13.504615384615386,13.87923076923077,14.253846153846155,14.62846153846154,15.003076923076923,15.377692307692309,15.752307692307692,16.126923076923077,16.501538461538463,16.876153846153848,17.25076923076923,17.625384615384615,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.13,13.243076923076924,13.356153846153846,13.46923076923077,13.582307692307692,13.695384615384615,13.80846153846154,13.921538461538463,14.034615384615385,14.147692307692308,14.260769230769231,14.373846153846154,14.486923076923077,{"y":14.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.13,12.735384615384616,12.340769230769231,11.946153846153846,11.551538461538462,11.156923076923077,10.762307692307694,10.367692307692309,9.973076923076924,9.57846153846154,9.183846153846154,8.78923076923077,8.394615384615385,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.25,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.8,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.69,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.54,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$18.00

Average Price Target$14.60

Lowest Price Target$8.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$10

Hold

-0.89%

Downside

Reiterated

07/30/25

LifeMD's stock score is primarily influenced by its financial performance challenges, notably persistent profitability issues and negative equity. The technical analysis indicates weak momentum, further weighing down the score. Although positive sentiment from the earnings call and strategic growth initiatives provide optimism, they are not enough to offset the fundamental financial concerns.

Brooks O'NeilLake Street

Lake Street

$18

Buy

78.39%

Upside

Reiterated

07/10/25

LifeMD (LFMD) Gets a Buy from Lake Street

David LarsenBTIG

BTIG

$15→$18

Buy

78.39%

Upside

Reiterated

06/18/25

Analysts Offer Insights on Healthcare Companies: Zai Lab (NASDAQ: ZLAB), LifeMD (NASDAQ: LFMD) and Novo Nordisk (NYSE: NVO)

Sarah JamesCantor Fitzgerald

Cantor Fitzgerald

$15

Buy

48.66%

Upside

Reiterated

05/07/25

Cantor Fitzgerald reiterates Overweight Rating on LifeMD Inc (LFMD)Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $15.00 price target on LifeMD Inc (NASDAQ: LFMD).

Steven ValiquetteMizuho Securities

Mizuho Securities

$7→$8

Hold

-20.71%

Downside

Reiterated

05/07/25

LifeMD Inc (LFMD) PT Raised to $8 at MizuhoMizuho analyst Steven Valiquette raised the price target on LifeMD Inc (NASDAQ: LFMD) to $8.00 (from $7.00) while maintaining a Neutral rating.

Yi ChenH.C. Wainwright

H.C. Wainwright

$14

Buy

38.75%

Upside

Reiterated

05/07/25

LifeMD's Strong Financial Performance and Strategic Initiatives Justify Buy Rating

Scott SchoenhausKeyBanc

KeyBanc

$7.5→$7

Buy

-30.62%

Downside

Reiterated

04/16/25

LifeMD Inc (LFMD) PT Lowered to $7 at KeyBancKeyBanc analyst Steve Dechert lowered the price target on LifeMD Inc (NASDAQ: LFMD) to $7.00 (from $7.50) while maintaining a Overweight rating.

Ilya ZubkovFreedom Capital Markets

Freedom Capital Markets

$12→$13

Buy

28.84%

Upside

Reiterated

03/18/25

LifeMD Inc (LFMD) PT Raised to $13 at Freedom BrokerFreedom Broker analyst Ilya Zubkov raised the price target on LifeMD Inc (NASDAQ: LFMD) to $13.00 (from $12.00) while maintaining a Buy rating

Alex FuhrmanLucid Capital

Lucid Capital

―

Buy

―

Reiterated

03/10/25

Craig-Hallum Sticks to Its Buy Rating for LifeMD (LFMD)

Kyle BauserRoth MKM

Roth MKM

$11→$12

Buy

18.93%

Upside

Reiterated

11/08/24

LifeMD price target raised to $12 from $11 at B. RileyLifeMD price target raised to $12 from $11 at B. Riley

William WoodB.Riley Financial

B.Riley Financial

$12→$11

Buy

9.02%

Upside

Reiterated

08/08/24

LifeMD's Consistent Growth and Margin Improvement Reinforce Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$10

Hold

-0.89%

Downside

Reiterated

07/30/25

Brooks O'NeilLake Street

Lake Street

$18

Buy

78.39%

Upside

Reiterated

07/10/25

LifeMD (LFMD) Gets a Buy from Lake Street

David LarsenBTIG

BTIG

$15→$18

Buy

78.39%

Upside

Reiterated

06/18/25

Analysts Offer Insights on Healthcare Companies: Zai Lab (NASDAQ: ZLAB), LifeMD (NASDAQ: LFMD) and Novo Nordisk (NYSE: NVO)

Sarah JamesCantor Fitzgerald

Cantor Fitzgerald

$15

Buy

48.66%

Upside

Reiterated

05/07/25

Cantor Fitzgerald reiterates Overweight Rating on LifeMD Inc (LFMD)Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $15.00 price target on LifeMD Inc (NASDAQ: LFMD).

Steven ValiquetteMizuho Securities

Mizuho Securities

$7→$8

Hold

-20.71%

Downside

Reiterated

05/07/25

LifeMD Inc (LFMD) PT Raised to $8 at MizuhoMizuho analyst Steven Valiquette raised the price target on LifeMD Inc (NASDAQ: LFMD) to $8.00 (from $7.00) while maintaining a Neutral rating.

Yi ChenH.C. Wainwright

H.C. Wainwright

$14

Buy

38.75%

Upside

Reiterated

05/07/25

LifeMD's Strong Financial Performance and Strategic Initiatives Justify Buy Rating

Scott SchoenhausKeyBanc

KeyBanc

$7.5→$7

Buy

-30.62%

Downside

Reiterated

04/16/25

LifeMD Inc (LFMD) PT Lowered to $7 at KeyBancKeyBanc analyst Steve Dechert lowered the price target on LifeMD Inc (NASDAQ: LFMD) to $7.00 (from $7.50) while maintaining a Overweight rating.

Ilya ZubkovFreedom Capital Markets

Freedom Capital Markets

$12→$13

Buy

28.84%

Upside

Reiterated

03/18/25

LifeMD Inc (LFMD) PT Raised to $13 at Freedom BrokerFreedom Broker analyst Ilya Zubkov raised the price target on LifeMD Inc (NASDAQ: LFMD) to $13.00 (from $12.00) while maintaining a Buy rating

Alex FuhrmanLucid Capital

Lucid Capital

―

Buy

―

Reiterated

03/10/25

Craig-Hallum Sticks to Its Buy Rating for LifeMD (LFMD)

Kyle BauserRoth MKM

Roth MKM

$11→$12

Buy

18.93%

Upside

Reiterated

11/08/24

LifeMD price target raised to $12 from $11 at B. RileyLifeMD price target raised to $12 from $11 at B. Riley

William WoodB.Riley Financial

B.Riley Financial

$12→$11

Buy

9.02%

Upside

Reiterated

08/08/24

LifeMD's Consistent Growth and Margin Improvement Reinforce Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering LifeMD

1 Month

xxx

Success Rate

15/32 ratings generated profit

Average Return

+9.89%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 46.88% of your transactions generating a profit, with an average return of +9.89% per trade.

3 Months

xxx

Success Rate

11/16 ratings generated profit

Average Return

+11.91%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +11.91% per trade.

1 Year

Alex FuhrmanLucid Capital

Success Rate

10/16 ratings generated profit

Average Return

+36.68%

reiterated a buy rating 5 months ago

Copying Alex Fuhrman's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +36.68% per trade.

2 Years

xxx

Success Rate

12/12 ratings generated profit

Average Return

+61.62%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +61.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LFMD Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LFMD has received 8 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. LFMD average Analyst price target in the past 3 months is 14.60.

Each month's total comprises the sum of three months' worth of ratings.

LFMD Financial Forecast

LFMD Earnings Forecast

Next quarter’s earnings estimate for LFMD is >-$0.01 with a range of -$0.07 to $0.03. The previous quarter’s EPS was $0.01. LFMD beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.21% of the time in the same period. In the last calendar year LFMD has Preformed in-line its overall industry.

LFMD Sales Forecast

Next quarter’s sales forecast for LFMD is $66.34M with a range of $65.30M to $68.00M. The previous quarter’s sales results were $65.70M. LFMD beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.44% of the time in the same period. In the last calendar year LFMD has Preformed in-line its overall industry.

LFMD Stock Forecast FAQ

What is LFMD’s average 12-month price target, according to analysts?

Based on analyst ratings, LifeMD’s 12-month average price target is 14.60.

What is LFMD’s upside potential, based on the analysts’ average price target?

LifeMD has 44.70% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LFMD a Buy, Sell or Hold?

LifeMD has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.

What is LifeMD’s price target?

The average price target for LifeMD is 14.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $18.00 ,the lowest forecast is $8.00. The average price target represents 44.70% Increase from the current price of $10.09.

What do analysts say about LifeMD?

LifeMD’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of LFMD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

LifeMD (LFMD) Stock Forecast & Price Target

LFMD Analyst Ratings

LFMD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering LifeMD

LFMD Analyst Recommendation Trends

LFMD Financial Forecast

LFMD Earnings Forecast

LFMD Sales Forecast

LFMD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts